Special Guidance on DEA’s COVID-19 Response Concerning the Production of Controlled Substance Medications
As the global pandemic progresses, the Diversion Control Division has been assuring the public that there is an adequate supply of controlled substances in the U.S., while also preventing the diversion of these controlled substances.
To learn more about this current topic join Hunter DeKoninck as he participates in the webinar "Special Guidance on DEA's COVID-19 Response Concerning the Production of Controlled Substance Medications" on Wednesday, June 3. The webinar will review the DEA's COVID-19 responses, identify challenges for suspicious order monitoring during the global pandemic and how to overcome due diligence road blocks while social distancing.
To register for this event click here.